METHODS  Sprague-Dawley rats and Beagle dogs were treated intravenously or intramuscularly for  consecutive days with doses of up to  mg/kg artesunate, evaluating toxicity, kinetics, genotoxicity, and cardiovascular and central nervous safety parameters after single and -week RESULTS  Artesunate was well tolerated with no mortality and only minor effects on clinical CONCLUSIONS  The results obtained in these studies support the safe use of artesunate in (which was not certified by peer review) is the author/funder
;    Exposure in terms of AUC is displayed for female and male rats after a single (D) and repeated (D) intravenous (IV) or intramuscular (IM) treatment with  mg artesunate/kg bw/day for artesunate (AS, left four bars per dose group) and its main metabolite dihydroartemisinin (DHA, right four bars per dose group)